



Webcast Alert: Aastrom to Host Fourth Quarter Investor Conference Call

ANN ARBOR, Mich., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast:

What: Aastrom Biosciences, Inc. Fourth Quarter Fiscal Year 2010 Investor Conference Call

When: Tuesday, August 17, 2010 @ 4:00 pm (ET)

Where: <http://www.aastrom.com/investor.cfm>

How: The conference call will be available live in the Investors section of Aastrom's website at <http://www.aastrom.com/investor.cfm>. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary (RealPlayer or Windows Media Player). To participate in the live call by telephone, please call (877) 312-5881 and reference Aastrom's fourth quarter conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173. A podcast will also be available after the live event at <http://www.aastrom.com/events.cfm>.

Schedule this webcast into MS-Outlook calendar (click open when prompted): <http://apps.shareholder.com/PNWOutlook/t.aspx?m=43586&k=D09EE52E>

If you are unable to participate during the live call, the webcast will be available for replay at <http://www.aastrom.com/events.cfm> until November 17, 2010. A replay of the call will also be available until 12:00 am (ET) on Tuesday, August 31, 2010 by calling (800) 642-1687, or from outside the U.S. at (706) 645-9291. The passcode for the replay is 90781710.

About Aastrom Biosciences

Aastrom Biosciences is developing expanded autologous cellular therapies for use in the treatment of severe cardiovascular diseases. The company's proprietary cell-processing technology enables the production of cellular therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy. For more information, please visit Aastrom's website at www.aastrom.com.

The Aastrom Biosciences, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=7839>

CONTACT: Berry & Company
Media contact
Stephen Zoegall
212 253-8881
szoegall@berrypr.com

Aastrom Biosciences
Investor Contact
Kimberli O'Meara
734 930-5777
ir@aastrom.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.